Optimal utilisation of sulphonylureas in resource-constrained settings

Cardiovascular Journal of Africa

Volumn 25, Issue 2, 2014, Pages 83-85

  Naidoo, Poobalan ^a   Rambiritch, Virendra ^b   Butkow, Neil ^c   Saman, Selvarajah ^b  

^a Boehringer Ingelheim ZA   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Resource constrained settings; Sulphonylureas; Type 2 diabetes mellitus

Indexed keywords

SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ANTIDIABETIC ACTIVITY; DRUG COST; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; DIABETES MELLITUS, TYPE 2; ECONOMICS; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84901020162     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2014-007     Document Type: Review

References (30)

1. McGill JB. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. Curr Diabetes Rev 2012; 8(4): 257-267.
2. Mazzola N. Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag Care 2012; 18(1 Suppl): S17-26.
3. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580-591.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med 2008; 358: 2560-2572.
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129-139.
7. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006; 55(5 Suppl 1): S2-5.
8. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64(12): 1339-1358.
9. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complication 1994; 8(4): 201-203.
10. Sehra D, Sehra S, Sehra ST. Sulfonylureas: do we need to introspect safety again? Expert Opin Drug Saf 2011; 10(6): 851-861.
11. Holstein A, Egberts E-H. Risk of hypoglycaemia with oral anti-diabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 405-414.
12. Burge MR, Sood V, Sobhy TA, et al. Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes Obesity Metabolism 1999; 1: 199-206.
13. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363(15): 1410-1418.
14. Klimt CR, Knatterud GL, Meinert CL, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19: 747-830.
15. Phung OJ, Schwartzman E, Allen RW, et al. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013; 30(10): 1160-1171.
16. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15(10): 938-953.
17. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10(4): 289-301.
18. Rambiritch V, Naidoo P, Butkow N. Dose-response relationships of sulfonylureas: will doubling the dose double the response? South Med J 2007; 100(11): 1132-1136.
19. Rambiritch V, Naidoo P. Gliclazide modified release. Drugs 2005; 65(10): 1449-1450.
20. Ikem I, Sumpio BE. Cardiovascular disease: the new epidemic in sub-Saharan Africa. Vascular 2011; 19(6): 301-307.
21. Mollentze WF, Levitt NS, Delport R, et al. Round-table discussion: Management of the diabetic patient in a resource constrained environment. S Afr J Diabetes Vasc Dis 2009; 6(2): 66-73.
22. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; 33(9): 984-999.
23. Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
24. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-1326.
25. Labuzek K, Kozłowski M, Szkudłapski D, et al. Incretin-based therapies in the treatment of type 2 diabetes-more than meets the eye? Eur J Intern Med 2013; 24(3): 207-212.
26. ADA/EASD/IDF Statement Concerning the Use of Incretin Therapy and Pancreatic Disease. http://www.diabetes.org/for-media/2013/recommendations-for. html. Accessed August 08/2013.
27. Tessier D, Dawson K. Tetrault JP. et al. Glibenclamide vs. gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11: 974-980.
28. Amod A, Ascott-Evans BH, Berg GI, et al. 2012 SEMDSA Guideline for the Management of Type 2 Diabetes. J Endocrinol Metabol Diabetes S Afr 2012; 17(2)(Suppl 1): S1-S95.
29. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulphonylureas. J Clin Epidemiol 1997; 50: 735-741.
30. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25(3): 245-254.